Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vicriviroc. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 known ✓ | P51681 | 20/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 16/20 | 0.84 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.84 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vicriviroc SCHEMBL15375740 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL4638191 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL4447817 | 1.00 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL29392831 | 0.96 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL19656878 | 0.95 | CCR5 (0.91) | CCR5CHRM2CHRM1CHRM3 | |
| Vicriviroc SCHEMBL3321008 | 0.95 | CCR5 (0.90) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14032029 | 0.92 | CCR5 (0.85) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13484306 | 0.92 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL15199622 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL10073358 | 0.91 | CCR5 (1.00) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9544 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4731611-A1 | TARGETED DEGRADERS OF HIV-1 NEF FOR THE TREATMENT OF HIV DISEASE | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260102422-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-04-16 | — | — | US | claimed |
| US-12595280-B2 | Phosphoramidates for the treatment of hepatitis B virus | EMORY UNIVERSITY (US) | 2026-04-07 | — | — | US | claimed |
| US-20260091068-A1 | METHODS FOR TREATING AND PREVENTING DISEASES | Tets, Viktor Veniaminovich (US) | 2026-04-02 | — | — | US | claimed |
| US-20260092059-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2026-04-02 | — | — | US | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-20070190067-A1 | Cationic Steroid Antimicrobial Compositions and Methods of Use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-08-16 | — | — | US | claimed |
| US-20070190558-A1 | Cationic Steroid Antimicrobial Compositions and Methods of Use | UNITED STATES GOVERNMENT - NATIONAL INSTITUTE OF HEALTH | 2007-08-16 | — | — | US | claimed |
| WO-2007089907-A2 | CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE | BRIGHAM YOUNG UNIVERSITY (US) | 2007-08-09 | — | — | WO | claimed |
| WO-2007089906-A2 | CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS FOR TREATING OR PREVENTING HERPES INFECTIONS | BRIGHAM YOUNG UNIVERSITY (US) | 2007-08-09 | — | — | WO | claimed |
| WO-2007087549-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| WO-2007087548-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | claimed |
| WO-2006129134-A1 | SYNERGIC COMBINATIONS COMPRISING A STYRYLQUINOLINE COMPOUND AND OTHER HIV INFECTION THERAPEUTIC AGENTS | BIOALLIANCE PHARMA (FR) | 2006-12-07 | — | — | WO | claimed |
| WO-2006096444-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-14 | — | — | WO | claimed |